Novartis Cosentyx® becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR)
Novartis' Cosentyx received FDA approval for polymyalgia rheumatica (PMR), its 11th US indication. The approval follows positive Phase III trial results showing sustained remission in PMR patients. Cosentyx is already approved for several immune-mediated diseases. Novartis plans to file for regulatory review in other countries, including Japan.
How this was made

The 30-second read
Why it matters
The FDA approval is a discrete regulatory milestone that can drive incremental expectations for Cosentyx’s immunology franchise, while the trial’s safety profile may influence near-term risk perception and uptake trajectory.
Market read
Traders can treat this as a new-indication regulatory catalyst for NVS, with immediate sentiment upside offset by attention to trial safety outcomes.
What to watch
Commercial impact will depend on how quickly PMR guidelines incorporate Cosentyx, real-world steroid taper feasibility, and whether post-marketing safety monitoring changes prescribing behavior.
Background
Cosentyx (secukinumab) is already approved for multiple immune-mediated inflammatory diseases; this article adds a new US indication for polymyalgia rheumatica (PMR) based on the REPLENISH Phase III program.
Ticker impact
Novartis’ Cosentyx received FDA approval as the first and only anti-IL-17 biologic for polymyalgia rheumatica, based on the REPLENISH Phase III trial.
Likely upward bias as the market prices in incremental revenue opportunity from a new indication, tempered by scrutiny of hypersensitivity, UTI, and rare fatal cryptococcal meningitis reported in the trial.
The article is a direct regulatory approval for Cosentyx in PMR with efficacy and safety details, which is typically material for biotech/pharma sentiment and positioning.
Market effects
Reinforces anti-IL-17 biologics’ expanding rheumatology footprint, potentially increasing competitive focus on steroid-sparing strategies in PMR.
US label expansion can shift prescribing and payer discussions in the US; Japan filing noted as a follow-on regulatory step.
Global PMR treatment landscape may reprice as additional regulators consider similar data from REPLENISH.
Counterpoint
The approval is for a specific dosing arm (150 mg) with notable infection/hypersensitivity rates, so uptake may be slower than bulls expect due to clinician comfort and payer restrictions.
Key entities
- companyNovartis
Issuer of Cosentyx; received FDA approval for Cosentyx in PMR.
- drugCosentyx (secukinumab)
Anti-IL-17A biologic; first and only FDA-approved anti-IL-17 biologic for PMR per the article.
- clinical_trialREPLENISH trial (NCT05767034)
Phase III study supporting the PMR approval; primary endpoint met at Week 52 after steroid taper.



